Compare Marqeta Inc (MQ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Marqeta Inc trades at $15.52 (market cap $1.62B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 51.4× Marqeta Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | REGN | |
|---|---|---|
Market Cap | $1.62B | $83.19B |
Sector | Technology | Health |
52-Week High | $26.00 | $812.27 |
52-Week Low | $15.04 | $555.51 |
Enterprise Value | $939.53M | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $15.96, down 4.37% on the day, with a bearish technical signal. The company reported Q2 2026 earnings with a beat on EPS and 17% net revenue growth, marking its second consecutive quarter of GAAP profitability. Recent partnerships with Google and Riskified highlight strategic expansion. However, valuation ratios remain elevated with a P/E of 177.28, and net income margin is thin at 1.53%.
The outlook is mixed; analyst consensus is a Buy with a $19.00 price target, implying upside, but execution on growth initiatives like stablecoin cards and European expansion is key. Risks include high valuation sensitivity and competitive pressures in fintech. Positive cash flow trends and recent profitability improvements provide a foundation for cautious optimism.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
